Immunotherapy has transformed the management of genitourinary cancers, offering durable responses in selected patient groups. However, the clinical benefit of immune checkpoint inhibitors varies significantly across renal cell carcinoma, urothelial carcinoma, and prostate cancer, underscoring the need for reliable predictive biomarkers. This review summarizes current knowledge on established and emerging biomarkers, including PD L1 expression, tumor mutational burden, molecular subtypes, genomic alterations, tumor microenvironment characteristics, circulating biomarkers, microbiome influences, and multi omic integrative approaches. We discuss their potential clinical relevance, limitations, and applicability across different tumor types. Future directions emphasize the development of composite biomarkers, standardization of testing platforms, real time monitoring strategies, and the integration of advanced technologies such as artificial intelligence and spatial profiling. Understanding and validating these biomarkers will be essential for optimizing personalized immunotherapy in genitourinary cancers.
Predictive biomarkers in cancer immunotherapy for genitourinary malignancies / Paulet, A., Shtembari, K., Izzi, M., Calandrelli, C., Mancini, S., Mela, M.M., Rossi, V., Giorgione, R., Pillozzi, S., Antonuzzo, L., Roviello, G.. - In: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. - ISSN 1879-0461. - ELETTRONICO. - 227:(2026), pp. 105575.1-105575.10. [10.1016/j.critrevonc.2026.105575]
Predictive biomarkers in cancer immunotherapy for genitourinary malignancies
Paulet, Alexandra;Shtembari, Kristian;Izzi, Martina;Calandrelli, Chiara;Mancini, Silvia;Rossi, Virginia;Giorgione, Roberta;Pillozzi, Serena;Antonuzzo, Lorenzo;Roviello, Giandomenico
2026
Abstract
Immunotherapy has transformed the management of genitourinary cancers, offering durable responses in selected patient groups. However, the clinical benefit of immune checkpoint inhibitors varies significantly across renal cell carcinoma, urothelial carcinoma, and prostate cancer, underscoring the need for reliable predictive biomarkers. This review summarizes current knowledge on established and emerging biomarkers, including PD L1 expression, tumor mutational burden, molecular subtypes, genomic alterations, tumor microenvironment characteristics, circulating biomarkers, microbiome influences, and multi omic integrative approaches. We discuss their potential clinical relevance, limitations, and applicability across different tumor types. Future directions emphasize the development of composite biomarkers, standardization of testing platforms, real time monitoring strategies, and the integration of advanced technologies such as artificial intelligence and spatial profiling. Understanding and validating these biomarkers will be essential for optimizing personalized immunotherapy in genitourinary cancers.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1040842826004622-main.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
2.99 MB
Formato
Adobe PDF
|
2.99 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



